To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia
Department of Women's and Children's Health, Obstetrics-Gynecology Division, Karolinska Institute, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden; School of Community/Global Health, Claremont Graduate University, Claremont, CA, USA; Institute for Health Promotion and Disease Prevention Research, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Women's and Children's Health, Obstetrics-Gynecology Division, Karolinska Institute, Stockholm, Sweden.
Show others and affiliations
2021 (English)In: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 21, no 4, article id 240Article in journal (Refereed) Published
Abstract [en]

Women treated for high-grade cervical-intraepithelial-neoplasia (CIN) require long-term follow-up with high-risk human-papillomavirus (HPV) testing. Self-sampling for HPV is well-accepted among these patients, but its role in follow-up for this group requires investigation. The present study examined how well HPV findings from self-sampled vaginal (VSS) and urine specimens correctly identified women from this cohort with recurrent CIN2+ compared with samples collected by clinicians. At 1st post-conization follow-up, 531 patients (99.8% participation) gave urine samples, performed VSS, underwent colposcopy with punch biopsy of visible lesions and clinician-collected cervical sampling for HPV analysis and liquid-based cytology. A total of 113 patients with positive HPV and/or abnormal cytology at 1st follow-up underwent 2nd follow-up. At 1st follow-up, all patients with recurrent CIN3 had positive HPV results by all methods. Clinician sampling and VSS revealed HPV16 positivity in 50% of recurrent cases and urine sampling revealed HPV16 positivity in 25% of recurrent cases. At 2nd follow-up, all 7 newly-detected CIN2/3 recurrences were associated with HPV positivity on VSS and clinician-samples. Only clinician-collected samples detected HPV positivity for two adenocarcinoma-in-situ recurrences, and both were HPV18 positive. A total of 77 patients had abnormal cytology at 1st follow-up, for which HPV positivity via VSS yielded highest sensitivity. The HPV findings were positive from VSS in 12 patients with high-grade squamous-intraepithelial-lesions (HSIL), and 11 patients with HSIL had positive HPV findings in clinician-collected and urine samples. All methods for assessing HPV presence yielded significant age-adjusted odds ratios for predicting abnormal lesions at 1st follow-up. For overall HPV results, Cohen's kappa revealed substantial agreement between VSS and clinician sampling, and moderate agreement between urine and clinician sampling. Clinician sampling and VSS were highly concordant for HPV16. Insofar as the pathology was squamous (not glandular), VSS appeared as sensitive as clinician sampling for HPV in predicting outcome among the present cohort. Since VSS can be performed at home, this option can maximize participation in the required long-term follow-up for these women at high-risk.

Place, publisher, year, edition, pages
Spandidos Publications , 2021. Vol. 21, no 4, article id 240
Keywords [en]
CIN, papillomavirus infections, predictive value of tests, self-care, specimen handling/methods
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-90248DOI: 10.3892/ol.2021.12501ISI: 000619109600001PubMedID: 33664804Scopus ID: 2-s2.0-85100615947OAI: oai:DiVA.org:oru-90248DiVA, id: diva2:1535227
Funder
Swedish Cancer Society, 110544 CAN2011/471Center for Integrated Cancer Studies at Karolinska Institutet - an environment for translational cancer research, 5888/05-722Swedish Research Council, 521-2008-2899Stockholm County Council, 20130097, 20160155King Gustaf V Jubilee Fund, 154022, 151202Available from: 2021-03-08 Created: 2021-03-08 Last updated: 2021-03-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Mints, Miriam

Search in DiVA

By author/editor
Mints, Miriam
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Oncology Letters
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 90 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf